CVS Removes Humira From Formularies, Senate Mulls Biosimilars Reforms

By Luke Zarzecki / January 4, 2024 at 4:48 PM
CVS will remove Humira from its commercial formularies in favor of covering the immunosuppressive drug’s biosimilars starting April 1, the major retail pharmacy chain announced in a statement Wednesday (Jan. 3). The move comes after Humira manufacturer AbbVie prevented biosimilars from gaining market share, and as lawmakers are attempting to increase biosimilar uptake through drug-pricing and pharmacy benefit manager (PBM) reforms. CVS says in a news release the decision will potentially lower costs for its customers by more than 50%...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.